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A B S T R A C T
Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after
benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam
failure. We report a case of simple motor status epilepticus refractory to benzodiazepines and multiple
anti-epileptic medications (AEDs) over 4 days. The addition of lacosamide in combination with existing
levetiracetam aborted the continuous seizure with maintenance of seizure freedom through the most
recent follow-up at 4 weeks.
Published by Elsevier Ireland Ltd on behalf of British Epilepsy Association.
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Lacosamide was approved as an adjunct therapy for the
treatment of partial-onset seizures by the European Commission
in September 2008 and by the US FDA in October 2008. Here we
present a patient with simple motor status epilepticus that was
successfully aborted with the addition of lacosamide to levetir-
acetam when three other AEDs failed.
2. Case description
A 57-year-old man from Eritrea with cognitive and language
impairment from traumatic brain injury suffered at age 25
presented with right arm and leg weakness. Because of his
baseline communication difﬁculties, his family provided the
history. They described a two-day history of repeatedly dropping
objects held in his right hand and accompanying falls. The right
arm and right leg weakness was static and accompanied by
involuntary jerking movements. His remote history of traumatic
brain injurywas followed 7 years later by the onset of epilepsy that
had been treated with phenytoin monotherapy without known
seizure recurrence. On examination, he was oriented only to* Corresponding author at: 710 Westwood Plz Rm 1-240 (Box 951769), Los
Angeles, CA 90095, United States. Tel.: +1 310 825 6681/+1 510 682 8815;
fax: +1 310 206 4733.
E-mail address: llchen@mednet.ucla.edu (Leo L.K. Chen).
1059-1311/$ – see front matter . Published by Elsevier Ireland Ltd on behalf of British
doi:10.1016/j.seizure.2010.11.004himself and not to date or place. Speech was non-ﬂuent with
frequent perseveration of the word ‘‘exceptionally.’’ Cooperation
existed for only simple commands. A mild pronator drift of the
right arm was present and right upper extremity grip was slightly
weaker than left. Tone within the right hand was mildly increased.
When at rest, a low-amplitude 1 Hz rhythmic thumb contraction
was present. EEG revealed persistent left posterior slowing and
frequent left occipital epileptiform rhythms that often spread to
include the centroparietal region (Fig. 1). MRI demonstrated cystic
encephalomalacia of the left parietal, occipital, and posterior
temporal lobes with an area of DWI/FLAIR hyperintensity
consistent with ongoing focal seizures (Fig. 2).
In the emergency room, 2 mg of IV lorazepam was adminis-
tered. Phenytoin serum concentration on admission was 4 mcg/ml
and the patient was loaded with 1000 mg of intravenous
fosphenytoin followed by 3000 mg of intravenous levetiracetam.
Maintenance doses of phenytoin 360 mg daily and levetiracetam
1500 mg twice daily were then started. Laboratory studies
including hematologic and chemistry panels with calcium,
magnesium, and liver enzymes were normal. Continuous EEG
monitoring was started 4 h after his initial presentation, which
demonstrated that his seizures brieﬂy subsided with residual
persistent left posterior slowing and frequent epileptiform
discharges over the left posterior region. However, frequent
electrographic seizures returned on the subsequent day with
durations of 50–60 s and localization restricted to the left posterior
region despite administering another 2 mg of lorazepam intrave-
nously. The epileptic movements of the right hand occurred withEpilepsy Association.
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Fig. 1. EEG on admission with focal electrographic seizures evolving over the left posterior region (red arrow). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of the article.)
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right hand dysfunction. Intravenous valproate was loaded at a dose
of 20 mg/kg and maintained at 10 mg/kg every 6 h. This was
continued for 33 h but was not effective in controlling the seizures.
The levetiracetam dose was then increased to 2000 mg twice daily
and the phenytoin dose was increased to achieve a serum
concentration in the range of 20–30 mcg/ml. Despite these
changes, electrographic seizures continued to occur four to eight
times an hour and behavioral seizures occurred one to two times
every 2 h. Several seizures occurred during meals, at which time
the patient was noted to be unable to feed himself using his right
hand.
After 4 days of refractory focal motor status epilepticus with
EEG monitoring, oral lacosamide tablet was started at 50 mg twice
daily given the refractory nature of the seizures to standard
treatment. The oral formulation was chosen because it provided
sufﬁciently fast introduction of the medication; though in
retrospect, IV formulation should have been considered given
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Fig. 2.MRI on admission showing the extensive left hemisphere encephalomalacia
and abnormal hyperintensity over the left posterior region on (A) FLAIR and (B) DWI
images.the desire to stop the seizures as soon as possible. ECG prior to
initiation of lacosamide was normal. Phenytoin was tapered to
discontinuation by 100 mg per day every two days to minimize
side effects from polytherapy. Valproate was tapered to discontin-
uation by 500 mg/day every 2 days because of drowsiness and a
rising serum ammonia concentration. With levetiracetam contin-
ued use, the electrographic seizures stopped on the forth day after
lacosamide was started. The right hand function improved and no
other potentially confounding provoking factors were found. After
ﬁve days on lacosamide 50 mg twice a day, the dosage was titrated
up 100 mg twice a day for 3 days, then to 200 mg twice a day. The
patient remained seizure free for 5 days on EEG monitoring before
hewas discharged home on levetiracetam2000 mg twice daily and
lacosamide 200 mg twice daily without any side effects such as
drowsiness or dizziness.
Onemonth later, the patient returned for outpatient care. There
had been no seizure recurrence. A repeat EEG showed moderate
left hemispheric slowing without epileptiform discharges.
3. Discussion
Lacosamide is approved as an adjunctive therapy for the
treatment of partial-onset seizures. Since its introduction, there
has been one reported case of successful use in the treatment of
non-convulsive status epilepticus1 and one reported case of
successful treatment of convulsive status epilepticus2 in the
English literature. There is also a case of successful treatment with
lacosamide in partial status epilepticus in Spanish.3 As is
commonly observed and previously described, seizure control
becomes progressivelymore difﬁcult to achievewith time,4 andwe
observed this difﬁculty with our patient who had refractory
seizures over 4 days despite a combination of phenytoin, valproate,
and levetiracetam. Our eventual successful treatment with
lacosamide further supports the potential of this medication to
treat refractory status epilepticus. While seizure resolution
independent of lacosamide’s use for this patient remains a
possibility, a beneﬁt from lacosamide is likely because seizure
resolution occurred within 24 h of the ﬁrst lacosamide dose while
other AEDs were tapered off quickly.
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refractory simple motor SE with the addition of lacosamide. The
beneﬁt we observed may have been due to lacosamide or due to a
combination of lacosamide with levetiracetam. Given that
lacosamide has a different mechanism of action from other AEDs,
including its ability to enhance the slow inactivation of voltage-
gated sodium channels,5 combination therapy should be explored.
We also demonstrated that rapid oral lacosamide titration
reaching 400 mg total daily in 8 days can be used in urgent
situations without signiﬁcant side effects. Recently published6,
Kellinghaus et al. reported a larger series of patients treatedwith IV
lacosamide at the 2009 American Epilepsy Society meeting, and
ultimately, more case series or a controlled trial would be
necessary to further elucidate lacosamide’s beneﬁt in simple
motor SE.
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